Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Cash Flow: 2021-2025

Historic Net Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $39.1 million.

  • Krystal Biotech's Net Cash Flow rose 40.11% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 2411.52%. This contributed to the annual value of -$13.0 million for FY2024, which is 106.62% down from last year.
  • As of Q3 2025, Krystal Biotech's Net Cash Flow stood at $39.1 million, which was down 11.18% from $44.0 million recorded in Q2 2025.
  • Krystal Biotech's Net Cash Flow's 5-year high stood at $135.1 million during Q2 2023, with a 5-year trough of -$72.6 million in Q2 2021.
  • Moreover, its 3-year median value for Net Cash Flow was $491,000 (2024), whereas its average is $20.9 million.
  • Data for Krystal Biotech's Net Cash Flow shows a peak YoY increase of 441.54% (in 2025) and a maximum YoY decrease of 7,486.15% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Krystal Biotech's Net Cash Flow stood at $54.6 million in 2021, then crashed by 144.79% to -$24.5 million in 2022, then skyrocketed by 39.62% to -$14.8 million in 2023, then plummeted by 92.97% to -$28.5 million in 2024, then spiked by 40.11% to $39.1 million in 2025.
  • Its Net Cash Flow was $39.1 million in Q3 2025, compared to $44.0 million in Q2 2025 and -$36.3 million in Q1 2025.